Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Jennison Associates LLC

Jennison Associates LLC lowered its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 25.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 20,078 shares of the biopharmaceutical company’s stock after selling 6,812 shares during the quarter. Jennison Associates LLC’s holdings in Celldex Therapeutics were worth $796,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after acquiring an additional 300,406 shares during the period. GSA Capital Partners LLP lifted its position in Celldex Therapeutics by 192.0% during the 3rd quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company’s stock worth $1,231,000 after acquiring an additional 29,404 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at about $994,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Celldex Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock valued at $9,950,000 after buying an additional 10,818 shares during the period. Finally, Panoramic Investment Advisors LLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at about $258,000.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $36.30 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $22.11 and a twelve month high of $53.18. The business has a 50-day moving average price of $42.07 and a 200 day moving average price of $36.20.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million during the quarter, compared to analyst estimates of $1.20 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CLDX has been the subject of several analyst reports. Guggenheim boosted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.